Anticancer agent CHS-828 inhibits cellular synthesis of NAD

Biochemical and Biophysical Research Communications

Volumn 367, Issue 4, 2008, Pages 799-804

  Olesen, Uffe Høgh ^a,b   Christensen, Mette Knak ^b   Björkling, Fredrik ^b   Jäättelä, Marja ^c   Jensen, Peter Buhl ^b,d   Sehested, Maxwell ^a,b   Nielsen, Søren Jensby ^a,b  

^a Rigshospitalet   (Denmark)

^b BioAlliance Pharma   (France)

^c Institute of Cancer Biology   (Denmark)

^d FINSEN LABORATORY   (Denmark)

Author keywords

Cancer; CHS 828; FK866; Metabolism; NAD; Nampt; PBEF; Visfatin

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ENZYME; FK 866; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA REPAIR; DRUG INHIBITION; ENERGY YIELD; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYANIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANIDINES; HUMANS; LUNG NEOPLASMS; NAD; PIPERIDINES; SIGNAL TRANSDUCTION;

EID: 38649096263     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.01.019     Document Type: Article

References (34)

1. Frye R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260 (1999) 273-279
2. Ame J.C., Spenlehauer C., and de Murcia G. The PARP superfamily. Bioessays 26 (2004) 882-893
3. D'Amours D., Desnoyers S., D'Silva I., and Poirier G.G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342 Pt 2 (1999) 249-268
4. Haigis M.C., and Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20 (2006) 2913-2921
5. Saunders L.R., and Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26 (2007) 5489-5504
6. Beneke S., Diefenbach J., and Burkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int. J. Cancer 111 (2004) 813-818
7. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff H.J., Poirier G.G., Dawson T.M., and Dawson V.L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297 (2002) 259-263
8. van Wijk S.J., and Hageman G.J. Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. Free Radic. Biol. Med. 39 (2005) 81-90
9. Revollo J.R., Grimm A.A., and Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr. Opin. Gastroenterol. 23 (2007) 164-170
10. Hageman G.J., and Stierum R.H. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat. Res. 475 (2001) 45-56
11. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
12. Nomura F., Yaguchi M., Togawa A., Miyazaki M., Isobe K., Miyake M., Noda M., and Nakai T. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 15 (2000) 529-535
13. Pedersen P.L. The cancer cell's "power plants" as promising therapeutic targets: an overview. J. Bioenerg. Biomembr. 39 (2007) 1-12
14. Hasmann M., and Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 (2003) 7436-7442
15. Holen K., Saltz L.B., Hollywood E., Burk K., and Hanauske A.R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs (2007)
16. Khan J.A., Tao X., and Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol. 13 (2006) 582-588
17. Hjarnaa P.J., Jonsson E., Latini S., Dhar S., Larsson R., Bramm E., Skov T., and Binderup L. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 59 (1999) 5751-5757
18. Ravaud A., Cerny T., Terret C., Wanders J., Bui B.N., Hess D., Droz J.P., Fumoleau P., and Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur. J. Cancer. 41 (2005) 702-707
19. Hassan S.B., Lovborg H., Lindhagen E., Karlsson M.O., and Larsson R. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. Anticancer Res. 26 (2006) 4431-4436
20. Olsen L.S., Hjarnaa P.J., Latini S., Holm P.K., Larsson R., Bramm E., Binderup L., and Madsen M.W. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int. J. Cancer 111 (2004) 198-205
21. de Leij L., Postmus P.E., Buys C.H., Elema J.D., Ramaekers F., Poppema S., Brouwer M., van der Veen A.Y., Mesander G., and The T.H. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res. 45 (1985) 6024-6033
22. Jensen P.B., Sorensen B.S., Sehested M., Demant E.J., Kjeldsen E., Friche E., and Hansen H.H. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem. Pharmacol. 45 (1993) 2025-2035
23. Schou C., Ottosen E.R., Petersen H.J., Björkling F., Latini S., Hjarnaa P.V., Bramm E., and Binderup L. Novel cyanoguanidines with potent oral antitumour activity. Bioorg. Med. Chem. Lett. 7 (1997) 3095-3100
24. Jensen P.B., Christensen I.J., Sehested M., Hansen H.H., and Vindelov L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br. J. Cancer. 67 (1993) 311-320
25. Ekelund S., Larsson R., and Nygren P. Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells. Anticancer Res. 22 (2002) 2269-2274
26. Ekelund S., Liminga G., Bjorkling F., Ottosen E., Schou C., Binderup L., and Larsson R. Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine. Biochem. Pharmacol. 60 (2000) 839-849
27. Ekelund S., Nygren P., and Larsson R. Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. Biochem. Pharmacol. 61 (2001) 1183-1193
28. Martinsson P., Liminga G., Dhar S., de la Torre M., Lukinius A., Jonsson E., Bashir Hassan S., Binderup L., Kristensen J., and Larsson R. Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. Eur. J. Cancer 37 (2001) 260-267
29. A. Roulston, C. Bernier, H. Chan, M.O. Gratton, A. Jang, E. Koch, M. Lavoie, D. Paquette, M. Mitchell, A. Berger, L. Belee, X. Billot, G. Shore, P. Beauparlant, in: Molecular Targets and Cancer Therapeutics, AACR, San Francisco, California, 2007, p. A81.
30. Martinsson P., de la Torre M., Binderup L., Nygren P., and Larsson R. Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur. J. Pharmacol. 417 (2001) 181-187
31. Martinsson P., Ekelund S., Nygren P., and Larsson R. The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro-from cytotoxic synergy to complete inhibition of apoptosis. Br. J. Pharmacol. 137 (2002) 568-573
32. Lovborg H., Martinsson P., Gullbo J., Ekelund S., Nygren P., and Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem. Pharmacol. 63 (2002) 1491-1498
33. Hansen C.M., Hansen D., Holm P.K., Larsson R., and Binderup L. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. Anticancer Res. 20 (2000) 4211-4220
34. Gullbo J., Lovborg H., Dhar S., Lukinius A., Oberg F., Nilsson K., Bjorkling F., Binderup L., Nygren P., and Larsson R. Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anticancer Drugs 15 (2004) 45-54